It is easy to talk about due diligence in the abstract, but it is much harder to practice what you preach. One of the hardest things about early stage investing is that it is really risky – if you don’t have some suspension of disbelief, and you obsess too much about cataloging every risk, you will never get a deal done. As a way of wrapping up this series of articles with a review, let’s take a look at a few common mistakes and see what we can learn from them.
- Delta Development Team – Introducing BloodCOMM Premium
- Special Operations Forces Blood Cooler from Delta Development
- UACI startup alumni Reglagene making impressive strides in brain cancer treatment
- Reglagene RGN6024 Cover Story August 2025 Molecular Cancer Therapeutics
- Calls for More Angel Investing
- Takes a Licking and Keeps on Ticking
- Ventura County firefighters make history with in-the-field blood transfusions
- FireRescue1’s “3 Things We’re Watching at FDIC 2025
- Delta Ice 1L debut at New Castle Blood Symposium
- The next evolution in Prehostial Blood Management